达帕格利弗洛辛可以缓解糖尿病病
Yi-Hui Wang1,2, Dong-Yuan Chang1,3, Ming-Hui Zhao1,2,3
1Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
Antioxidants & redox signaling
|June 5, 2023
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 通过减少铁亡,减轻糖尿病病. 这项研究表明,SGLT2i通过向HIF1α/HO1通路来保护脏,减轻氧化应激和损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病病 (DKD) 是末期病的主要原因之一.
- -葡萄糖共运输体2抑制剂 (SGLT2i) 提供脏保护,但机制尚不清楚.
- 与氧化应激相关的铁,与DKD进展有关.
研究的目的:
- 调查SGLT2i是否可以减轻DKD中的铁和损伤.
- 探索HIF1α/HO1轴在SGLT2i介导脏保护中的作用.
主要方法:
- 使用db/db小鼠和高葡萄糖/高脂肪 (HG/HF) 处理的HK-2细胞来建模DKD.
- 评估铁灭症标志物,氧化应激和铁含量.
- 检查了缺氧诱导因子1α (HIF1α) 和血氧酶1 (HO1) 的表达以及达帕格利弗洛辛的作用.
主要成果:
- DKD模型表现出铁灭的标志物,包括脂质过氧化,抗氧化能力降低和铁过载.
- 在DKD模型中观察到HIF1α和HO1表达的增加.
- 达帕格利弗洛辛治疗减弱了铁和HIF1α/HO1轴的激活.
- 操纵HIF1α/HO1水平影响HK-2细胞中的铁亡.
结论:
- 在DKD中,SGLT2i具有脏保护作用,部分通过抑制铁亡.
- HIF1α/HO1通路是DKD中铁亡的关键调解者.
- 通过HIF1α/HO1轴向铁亡是一种潜在的DKD治疗策略.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
01:24Glucagon-like Receptor Agonists
370
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
370
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
658
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
658
01:28Chronic Kidney Disease III: Interprofessional Care
50
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
50